



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Page

1

of

Complete if Known

Application Number	09/905,160
Filing Date	July 12, 2001
First Named Inventor	
Art Unit	1648
Examiner Name	Park

Attorney Docket Number

014058-012830US

RECEIVED  
JUL 18 2003  
TECH CENTER 1600/2900

## U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear <i>clam 101</i>
		Number Kind Code <sup>2</sup> (if known)			
AA	US 6,355,257		03-12-2002	Johnson et al.	
AB	US-				
AC	US-				
AD	US-				
AE	US-				
AF	US-				
AG	US-				
AH	US-				
AI	US-				
AJ	US-				
AK	US-				
AL	US-				
AM	US-				
AN	US-				
AO	US-				
AP	US-				
AQ	US-				
AR	US-				
AS	US-				
AT	US-				

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
AU							<input type="checkbox"/>
AV							<input type="checkbox"/>
AW							<input type="checkbox"/>
AX							<input type="checkbox"/>
AY							<input type="checkbox"/>
AZ							<input type="checkbox"/>
BA							<input type="checkbox"/>
BB							<input type="checkbox"/>

Examiner Signature

Date Considered

11/17/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

2

of

Complete if Known	
Application Number	09/905,160
Filing Date	July 12, 2001
First Named Inventor	
Art Unit	1648
Examiner Name	Park
Attorney Docket Number	014058-012830US

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	BC	
	BD	
	BE	
	BF	
	BG	
	BH	
	BI	
	BJ	
	BK	
	BL	
	BM	

Examiner Signature		Date Considered	11/12/03
--------------------	--	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.  
SF 1472606 v1

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 210121.489C1	APPLICATION NO. 09/905,160
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS David A. Johnson and C. Gregory Sowell	GROUP ART UNIT 1648
				FILING DATE July 12, 2001	

H4

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>hj</i>	AA	6,113,918	09/05/00	Johnson et al.	424	278.1	
<i>hj</i>	AB	4,912,094	03/27/90	Myers et al.	514	54	
<i>hj</i>	AC	B1 4,912,094	02/15/94	Meyers et al.	514	54	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION
							YES NO
<i>hj</i>	AD	WO 98/50399	11/12/98	WIPO			

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>hj</i>	AE	Baldridge, "Synthetic Adjuvants: Recent Developments and Applications," IBC Vaccine Conference, Washington DC, February 1998.
<i>hj</i>	AF	Bulusu et al., "Cyclic Analogues of Lipid A: Synthesis and Biological Activities," <i>J. Med. Chem.</i> 35(19): 3463-3469, 1992.
<i>hj</i>	AG	Eustache et al., "New Acyclic Analogues of Lipid A: Synthesis of 4-Phosphonoxybutyl and 3-Phosphonoxypropyl Glycosides of 2-Amino-2-Deoxy-D-Glucose," <i>Carbohydrate Research</i> 251:251-267, January 3, 1994.
<i>hj</i>	AH	Johnson et al., "Synthesis and Biological Evaluation of a New Class of Vaccine Adjuvants: Aminoalkyl Glucosaminide 4-Phosphates (AGPs)," <i>Bioorg. Med. Chem. Lett.</i> 9(15):2273-2278, Aug 2, 1999.
<i>hj</i>	AI	Ikeda et al., "Synthesis of Biologically Active N-Acylated L-serine Containing Glucosamine-4-Phosphate Derivatives of Lipid A," <i>Chem. Pharm. Bull.</i> 41(10): 1879-1881, 1993.
<i>hj</i>	AJ	Miyajima et al., "Lipid A and Related Compounds XXXI. Synthesis of Biologically Active N-Acylated L-Serine-Containing D-Glucosamine 4-Phosphate," <i>Chem. Pharm. Bull.</i> 44(12): 2268-2273, 1996.
<i>hj</i>	AK	Shimizu et al., "Antitumor Activity and Biological Effects of Chemically Synthesized Monosaccharide Analogues of Lipid A in Mice," <i>Chem. Pharm. Bull.</i> 33(10): 4621-4624, 1985.
<i>hj</i>	AL	Shimizu et al., "Biological Activities of Chemically Synthesized N-acylated Serine-linked Lipid A Analog in Mice," <i>Int. J. Immunopharmacol.</i> 16(8): 659-665, 1994.
<i>hj</i>	AM	Shimizu et al., "Biological Activities and Antitumor Effects of Synthetic Lipid A Analogs Linked N-Acylated Serine," <i>Int. J. Immunopharmacol.</i> 17(5): 425-431, 1995.

EXAMINER	DATE CONSIDERED
<i>hj</i>	
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).	